Successful oral desensitization with crizotinib after crizotinib‑induced hepatitis in an anaplastic lymphoma kinase‑rearranged non‑small‑cell lung cancer patient: A case report
- Authors:
- Published online on: June 29, 2017 https://doi.org/10.3892/mco.2017.1310
- Pages: 295-297
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Crizotinib is one of the molecularly‑targeted agents targeted against anaplastic lymphoma kinase (ALK)‑rearranged non‑small‑cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK‑rearranged NSCLC. Hepatic laboratory abnormalities are frequently observed with crizotinib and treatment discontinuation is occasionally required. We herein report the case of a 51‑year‑old woman diagnosed with relapsed ALK‑rearranged NSCLC, who received crizotinib as second‑line systemic chemotherapy. After 17 days of crizotinib therapy, the patient developed grade >3 hepatotoxicity. Treatment discontinuation improved the laboratory abnormalities and fifth‑line oral desensitization with crizotinib achieved successful response without hepatotoxicity. Therefore, oral desensitization with crizotinib may be a viable option following crizotinib‑induced hepatitis.
